Kala-azar treatment failing in Nepal

In a recent study, scientists have concluded that the cure rates of Miltefosine, the only oral drug for visceral leishmaniasis available, have significantly decreased. Miltefosine was introduced in the Indian subcontinent a decade ago. Despite adhering to the treatment, only 3 out of 4 patients treated with Miltefosine in Nepal today are being cured.

, also known as 'kala-azar', is the most severe form of leishmaniasis and fatal if not treated. The disease is the second-largest parasitic killer in the world, after malaria, and is endemic in the Indian subcontinent, , Latin America and Southern Europe. Early diagnosis and treatment are essential to save patients' lives, and to control the spreading of the disease.

There are very few drugs available to counter this neglected infectious disease. By the end of the 20th century, the kala-azar parasite showed such an increased resistance to injectable antimonial drugs that its use had to be abandoned on the Indian subcontinent.

When Miltefosine was first introduced as part of a regional campaign in the Indian subcontinent for kala-azar elimination a decade ago, the drug proved to be very effective. The recent study shows that this effectiveness has now decreased significantly in Nepal.

The scientists used two methods to check whether the patients truly took the drug, but found that they adequately adhered to the treatment. They also explored whether drug-resistance could explain this high , but so far no Miltefosine-resistant parasites were detected in patients.  This suggests that other mechanisms causing a reduction in the efficacy of Miltefosine may be at work.

"These results constitute an alarming signal for the kala-azar elimination campaign. Drug policies should be reviewed to achieve better cure rates and to protect the few available drugs. We are now investigating among other things what role super-parasites -very well adapted to manipulate human - may play and whether they are somehow responsible for the reduced efficacy of Miltefosine " said Jean-Claude Dujardin, coordinator of the Kaladrug-R project at the Institute of Tropical Medicine in Antwerp and senior author of the study.

The paper 'Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite , re-infection or non-compliance' is published in the latest issue of Clinical Infectious Diseases.

More information: Rijal, S. et al. Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, re-infection or non-compliance. Clin Infect Dis. 2013 Feb 20. www.ncbi.nlm.nih.gov/pubmed/23425958

add to favorites email to friend print save as pdf

Related Stories

Old drug shows new promise to treat leishmaniasis

Feb 02, 2012

(Medical Xpress) -- A study published yesterday shows that a drug called fexinidazole could potentially be used to treat visceral leishmaniasis, a parasitic disease that kills 50 000 to 60 000 people ...

Do our medicines boost pathogens?

Dec 21, 2011

Scientists of the Institute of Tropical Medicine (ITG) discovered a parasite that not only had developed resistance against a common medicine, but at the same time had become better in withstanding the human ...

Recommended for you

In US, Ebola fears rise but most confident in response

4 hours ago

After two health care workers in Texas were infected with Ebola while caring for a Liberian patient, a poll Tuesday showed a rattled US public that nevertheless stayed confident in the government's response.

'Humbled' NBC cameraman recovers from Ebola

5 hours ago

A US photojournalist said Tuesday he was grateful to be alive after the hospital treating him declared him now free of Ebola, in a minor victory over the virus that has killed more than 4,500 people.

User comments